Pharmaceutical Executive Daily: New Research on Ozempic
Today's Pharmaceutical Executive Daily covers key news in the pharmaceutical and life sciences industry.
FDA Approval of Lynkuet
The FDA has approved Bayer's Lynkuet (elinzanetant) for treating moderate to severe vasomotor symptoms associated with menopause.
- Lynkuet is the first dual neurokinin 1 and 3 receptor antagonist.
- Approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
Ozempic Research and Novartis Merger
New research suggests Ozempic may reduce biological age, and Novartis has a $12 billion merger agreement to acquire Avidity Biosciences.
No direct quotes available in the given text.
Author's summary: New pharmaceutical research and approvals.
More News
- Alleged Charlie Kirk assassin allowed to wear street clothes at trial
- Airports prepare for holiday travel as Government Shutdown continues | News Channel 3-12
- Waymo Co-CEO Tekedra Mawakana on What’s Next: Highways, Airports, New Cities
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Michael Clark murder defense seeks to link case to JonBenét investigation 'mistakes'
- Rolls-Royce Tests Pure Methanol Engine
- In Anish Kapoor’s Hands, an Offshore Gas Rig Became a Call for Climate Accountability
- FTM investigation: Big banks bet on planet failure - $1.6 Trillion allocated to fossil fuel industry
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- Richard White targeted as federal police raid WiseTech